Episode 176 - March 13, 2026

The Biotech Hangout panel discusses the biotech sector's resilience amidst global conflicts and rising interest rates, weighing the potential impacts on IPOs and overall market sentiment. The panel highlights positive data readouts and significant fundraising activities as indicators of sector strength, while also examining the implications of Vinay Prasad's departure from the FDA, particularly concerning rare disease drug approvals. Discussions extend to the FDA's merging of adverse event trackers and the biotech industry's 50th anniversary, with emphasis on drug pricing challenges. Additionally, the panel analyzes recent M&A deals, including Servier's acquisition of Day One, and explores promising data from companies like IDEAYA in uveal melanoma treatment.